An editorial update: Should she take aspirin?

Annals of Internal Medicine

Volumn 142, Issue 11, 2005, Pages 942-943

  Mulrow, Cynthia ^b   Pignone, Michael ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT;

CARDIOVASCULAR DISEASE; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; MIDDLE AGED; NOTE;

ASPIRIN; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; PRIMARY PREVENTION;

EID: 20344393627     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-11-200506070-00015     Document Type: Review

References (7)

1. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-72. [PMID: 11790072]
2. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized ttial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304. [PMID: 15753114]
3. Kjeldsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D, et al. Influence of gender and age on preventing cardiovascular disease by anrihypertensive tteatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Tteatment. J Hypettens. 2000;18: 629-42. [PMID: 10826567]
4. de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people ar cardiovascular risk: a randomised trial in genetal practice. Collaborarive Group of the Primary Prevention Project. Lancet. 2001;357:89-95. [PMID: 11197445]
5. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. [PMID: 11786451]
6. Levin RI, Harpel PC, Weil D, Chang TS, Rifkin DB. Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantity plasminogen activatot activity. J Clin Invest. 1984;74:571-80. [PMID: 6235245]
7. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review, aspirin resistance and its clinical implications. Ann Intern Med. 2005;142:370-80. [PMID: 15738456]